Last reviewed · How we verify

Sevoflurane Inhalation Liquid

Damanhour Teaching Hospital · FDA-approved active Small molecule

Sevoflurane is a volatile anesthetic that depresses the central nervous system by enhancing inhibitory GABA neurotransmission and inhibiting excitatory glutamate signaling.

Sevoflurane is a volatile anesthetic that depresses the central nervous system by enhancing inhibitory GABA neurotransmission and inhibiting excitatory glutamate signaling. Used for Induction and maintenance of general anesthesia in adults and pediatric patients, Anesthesia for surgical procedures.

At a glance

Generic nameSevoflurane Inhalation Liquid
SponsorDamanhour Teaching Hospital
Drug classVolatile general anesthetic
TargetGABA-A receptor, NMDA receptor
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Sevoflurane is a halogenated ether that acts as a general anesthetic by modulating multiple ion channels and neurotransmitter receptors in the brain. It enhances the activity of inhibitory GABA-A receptors while simultaneously blocking excitatory NMDA glutamate receptors, resulting in rapid loss of consciousness and anesthesia. The exact molecular mechanisms remain incompletely understood but involve disruption of neuronal signaling pathways essential for consciousness.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: